LONDON, April 18, 2023 /PRNewswire/ — NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement with Professor Chris Lords Laboratory at the Institute for Cancer Research, London. The collaboration will use NeoPhore’s proprietary small molecule DNA mismatch repair (‘MMR’) inhibitors to study the activity of a single agent against tumors with a defined genetic background.

Building on the breakthrough discoveries and ongoing research of its scientific founders and collaborators, NeoPhore is developing a pipeline targeting novel proteins in the DNA mismatch repair pathway for the treatment of cancer. The company’s world-class MMR modulators induce expression of neoantigens and enhance immunogenicity in solid tumors that are exceptionally sensitive to immunotherapy.

professor Chris Lord is Professor of Cancer Genomics and Associate Head of the Department of Breast Cancer Research at the Institute of Cancer Research (ICR) and Associate Head of the Breast Cancer Now Toby Robins Research Center and Cancer Research UK Gene Function Team at IKR.

professor Chris LordLead Researcher on the project from the ICR, said: “We are excited about this new collaboration with NeoPhore. Identifying new ways to treat cancer is central to many of our activities here at the ICR, and this project will focus precisely on that. We hope that by collaborating with NeoPhore we can find new vulnerabilities in cancer cells to target drugs that NeoPhore has discovered.”

DR Matthew BakerNeoPhore’s Chief Executive Officer stated: “We are delighted to be working with Prof. Chris Lord who is a prominent and respected researcher in this field. Access to his team’s scientific expertise will enable us to investigate novel mechanisms of action of MMR signaling in a variety of solid tumors. We believe this powerful collaboration has the potential to expand the use of MMR inhibitors beyond neoantigen…